Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

OBJECTIVE: To estimate the occurrence and relative risks of first-ever-incident non-cutaneous cancer overall and for 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment start, attained age, and duration of active treatment. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Huss, Viking, Bower, Hannah, Wadström, Hjalmar, Frisell, Thomas, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071561/
https://www.ncbi.nlm.nih.gov/pubmed/34324640
http://dx.doi.org/10.1093/rheumatology/keab570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071561/
https://www.ncbi.nlm.nih.gov/pubmed/34324640
http://dx.doi.org/10.1093/rheumatology/keab570

Ejemplares similares